文献速递肝病

外周血单个核细胞转录组学揭示HBV相关慢加急性肝衰竭发生中的免疫代谢紊乱

PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
PubMed 文献 · Gut · 2021-01-11

功能协同分析显示病毒过程与所有疾病阶段相关,免疫失调驱动CHB或LC向ACHD和ACLF进展,代谢紊乱在ACHD显著、在ACLF严重;干扰素、中性粒细胞和单核细胞相关先天免疫通路上调,适应性免疫相关特征下调,脂质和脂肪酸代谢紊乱见于ACLF发展过程;四个差异表达基因在患者和实验大鼠中验证,具作为HBV-ACLF发病生物标志物的潜力。

要点

  • HBV加剧触发的免疫代谢紊乱是HBV-ACLF的潜在机制
  • 先天免疫通路上调、适应性免疫下调伴随ACLF进展
  • 脂质和脂肪酸代谢紊乱在ACLF发展中观察到

核心结论

  • HBV加剧触发的免疫代谢紊乱是HBV-ACLF的潜在机制,可能为降低HBV-ACLF相关死亡率提供新的诊断和治疗靶点。

研究设计与样本

  • 其中65例受试者(ACLF 20例、ACHD 10例、LC 10例、CHB 10例、NC 15例)接受外周血单个核细胞mRNA测序。

主要发现

  • 聚焦PBMC反应相关的七个生物过程与前500个差异表达基因的功能协同分析显示,病毒过程与所有疾病阶段相关。
  • 免疫失调是HBV加剧触发的最突出变化和紊乱,驱动CHB或LC向ACHD和ACLF进展。
  • 代谢紊乱在ACHD显著、在ACLF严重;62个重叠差异表达基因分析进一步将HBV相关免疫代谢紊乱与ACLF进展联系起来。
  • 与先天免疫反应相关的干扰素、中性粒细胞和单核细胞相关通路特征显著上调,适应性免疫反应相关特征下调。
  • ACLF发展过程中观察到脂质和脂肪酸代谢紊乱;四个差异表达基因在患者和实验大鼠中外部验证,确认其特异性和作为HBV-ACLF发病生物标志物的潜力。

临床怎么用

  • PBMC转录组学特征(免疫代谢紊乱相关差异表达基因)可能作为HBV-ACLF的诊断和疗效监测生物标志物。
  • 先天免疫通路上调与适应性免疫下调的识别提示免疫调节可能是HBV-ACLF的潜在治疗方向。
  • 脂质和脂肪酸代谢紊乱的发现提示代谢干预或为降低HBV-ACLF相关死亡率的策略之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) pathophysiology remains unclear. This study aims to characterise the molecular basis of HBV-ACLF using transcriptomics. METHODS: Four hundred subjects with HBV-ACLF, acute-on-chronic hepatic dysfunction (ACHD), liver cirrhosis (LC) or chronic hepatitis B (CHB) and normal controls (NC) from a prospective multicentre cohort were studied, and 65 subjects (ACLF, 20; ACHD, 10; LC, 10; CHB, 10; NC, 15) among them underwent mRNA sequencing using peripheral blood mononuclear cells (PBMCs). RESULTS: The functional synergy analysis focusing on seven bioprocesses related to the PBMC response and the top 500 differentially expressed genes (DEGs) showed that viral processes were associated with all disease stages. Immune dysregulation, as the most prominent change and disorder triggered by HBV exacerbation, drove CHB or LC to ACHD and ACLF. Metabolic disruption was significant in ACHD and severe in ACLF. The analysis of 62 overlapping DEGs further linked the HBV-based immune-metabolism disorder to ACLF progression. The signatures of interferon-related, neutrophil-related and monocyte-related pathways related to the innate immune response were significantly upregulated. Signatures linked to the adaptive immune response were downregulated. Disruptions of lipid and fatty acid metabolism were observed during ACLF development. External validation of four DEGs underlying the aforementioned molecular mechanism in patients and experimental rats confirmed their specificity and potential as biomarkers for HBV-ACLF pathogenesis. CONCLUSIONS: This study highlights immune-metabolism disorder triggered by HBV exacerbation as a potential mechanism of HBV-ACLF and may indicate a novel diagnostic and treatment target to reduce HBV-ACLF-related mortality.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Li J, Liang X, Jiang J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF. Gut. 2021. PMID: 33431576. doi:10.1136/gutjnl-2020-323395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。